Rhenman & Partners Asset Management AB raised its stake in shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) by 55.6% during the 4th quarter, HoldingsChannel.com reports. The fund owned 280,000 shares of the company’s stock after purchasing an additional 100,000 shares during the quarter. Rhenman & Partners Asset Management AB’s holdings in Aerie Pharmaceuticals were worth $10,108,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Bank of Montreal Can lifted its stake in Aerie Pharmaceuticals by 40.2% during the 4th quarter. Bank of Montreal Can now owns 1,060 shares of the company’s stock valued at $38,000 after acquiring an additional 304 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Aerie Pharmaceuticals by 23.0% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,753 shares of the company’s stock valued at $99,000 after acquiring an additional 515 shares during the period. State Board of Administration of Florida Retirement System lifted its stake in Aerie Pharmaceuticals by 3.6% during the 4th quarter. State Board of Administration of Florida Retirement System now owns 19,031 shares of the company’s stock valued at $687,000 after acquiring an additional 660 shares during the period. Chartwell Investment Partners LLC lifted its stake in Aerie Pharmaceuticals by 3.2% during the 4th quarter. Chartwell Investment Partners LLC now owns 23,735 shares of the company’s stock valued at $857,000 after acquiring an additional 734 shares during the period. Finally, Teachers Advisors LLC lifted its stake in Aerie Pharmaceuticals by 1.1% during the 3rd quarter. Teachers Advisors LLC now owns 70,937 shares of the company’s stock valued at $4,366,000 after acquiring an additional 772 shares during the period.

In other news, Director Gerald D. Cagle bought 2,000 shares of the firm’s stock in a transaction on Friday, November 16th. The shares were bought at an average price of $41.75 per share, for a total transaction of $83,500.00. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Casey C. Kopczynski sold 11,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 2nd. The stock was sold at an average price of $35.21, for a total transaction of $387,310.00. Following the sale, the insider now owns 106,743 shares in the company, valued at approximately $3,758,421.03. The disclosure for this sale can be found here. Insiders sold a total of 33,000 shares of company stock worth $1,333,090 in the last quarter. Company insiders own 10.53% of the company’s stock.

Several equities analysts have issued reports on AERI shares. BidaskClub upgraded shares of Aerie Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Monday, October 15th. ValuEngine cut shares of Aerie Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, January 2nd. Mizuho reiterated a “buy” rating and issued a $77.00 price objective on shares of Aerie Pharmaceuticals in a research note on Wednesday, November 7th. Zacks Investment Research cut shares of Aerie Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, January 15th. Finally, Oppenheimer began coverage on shares of Aerie Pharmaceuticals in a research note on Monday, November 12th. They issued a “buy” rating and a $64.00 price objective on the stock. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company. Aerie Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $77.45.

Shares of NASDAQ:AERI opened at $40.39 on Monday. Aerie Pharmaceuticals Inc has a twelve month low of $32.18 and a twelve month high of $74.75. The company has a market capitalization of $1.84 billion, a PE ratio of -11.99 and a beta of 1.10.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2019/02/11/aerie-pharmaceuticals-inc-aeri-shares-bought-by-rhenman-partners-asset-management-ab.html.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

See Also: Diversification Important in Investing

Want to see what other hedge funds are holding AERI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aerie Pharmaceuticals Inc (NASDAQ:AERI).

Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.